ciprofloxacin has been researched along with Colitis Gravis in 52 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The fecal flora obtained from 13 patients with ulcerative colitis was examined at the beginning of a pouchitis episode before treatment, during treatment with metronidazole or ciprofloxacin, and during pouchitis-free periods." | 9.11 | Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. ( Gosselink, MP; Hop, WC; Laman, JD; Ruseler-van Embden, JG; Schouten, WR; van Lieshout, LM, 2004) |
| "Metronidazole is effective for the treatment of acute pouchitis after ileal pouch-anal anastomosis, but it has not been directly compared with other antibiotics." | 9.09 | A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. ( Achkar, JP; Bambrick, ML; Bevins, CL; Brzezinski, A; Fazio, VW; Lashner, BA; Ormsby, AH; Remzi, FH; Seidner, DL; Shen, B, 2001) |
| "In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis." | 8.31 | The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study. ( Barnes, EL; Desai, A; Kochhar, GS, 2023) |
| "Oral antibiotics, such as ciprofloxacin (CFX), are widely used for the treatment of acute and chronic pouchitis." | 7.96 | Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin. ( Fukushima, K; Kohyama, A; Saito, T; Watanabe, K, 2020) |
| "Pouch contents of patients with ongoing pouchitis or an episode within the previous year released significantly more hydrogen sulfide than did the contents of patients who never had an attack of pouchitis and those with longstanding inactive disease." | 7.73 | Association between fecal hydrogen sulfide production and pouchitis. ( Furne, JK; Levitt, MD; Madoff, RD; Ohge, H; Rothenberger, DA; Springfield, J, 2005) |
| "The fecal flora obtained from 13 patients with ulcerative colitis was examined at the beginning of a pouchitis episode before treatment, during treatment with metronidazole or ciprofloxacin, and during pouchitis-free periods." | 5.11 | Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. ( Gosselink, MP; Hop, WC; Laman, JD; Ruseler-van Embden, JG; Schouten, WR; van Lieshout, LM, 2004) |
| "Metronidazole is effective for the treatment of acute pouchitis after ileal pouch-anal anastomosis, but it has not been directly compared with other antibiotics." | 5.09 | A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. ( Achkar, JP; Bambrick, ML; Bevins, CL; Brzezinski, A; Fazio, VW; Lashner, BA; Ormsby, AH; Remzi, FH; Seidner, DL; Shen, B, 2001) |
| "For acute pouchitis, very low quality evidence suggests that ciprofloxacin may be more effective than metronidazole." | 4.91 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Holubar, SD; Pardi, DS; Sandborn, WJ; Singh, S; Stroud, AM, 2015) |
| " For the treatment of acute pouchitis (4 RCTS, 5 agents), ciprofloxacin was more effective at inducing remission than metronidazole." | 4.86 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Cima, RR; Holubar, SD; Pardi, DS; Sandborn, WJ, 2010) |
| "In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis." | 4.31 | The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study. ( Barnes, EL; Desai, A; Kochhar, GS, 2023) |
| "5%) used antibiotics for pouchitis, predominantly ciprofloxacin." | 4.12 | Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety. ( Avraham, Y; Banon, L; Bar, N; Cohen, NA; Dotan, I; Dubinsky, V; Gophna, U; Maharshak, N; Tulchinsky, H; Weiss, GA, 2022) |
| "Oral antibiotics, such as ciprofloxacin (CFX), are widely used for the treatment of acute and chronic pouchitis." | 3.96 | Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin. ( Fukushima, K; Kohyama, A; Saito, T; Watanabe, K, 2020) |
| "The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition." | 3.80 | Role of probiotics in the management of pouchitis. ( Guslandi, M, 2014) |
| "Pouch contents of patients with ongoing pouchitis or an episode within the previous year released significantly more hydrogen sulfide than did the contents of patients who never had an attack of pouchitis and those with longstanding inactive disease." | 3.73 | Association between fecal hydrogen sulfide production and pouchitis. ( Furne, JK; Levitt, MD; Madoff, RD; Ohge, H; Rothenberger, DA; Springfield, J, 2005) |
| "Approximately half the patients with ulcerative colitis who undergo restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) will subsequently have pouchitis, and among those patients, one fifth will have chronic pouchitis." | 3.30 | Vedolizumab for the Treatment of Chronic Pouchitis. ( Bressler, B; Danese, S; Escher, A; Feagan, BG; Ferrante, M; Gionchetti, P; Hart, A; Jairath, V; Jones, S; Lindner, D; Löwenberg, M; Shen, B; Silverberg, MS; Travis, S, 2023) |
| "To evaluate the potential for pharmacokinetic interactions between MMX mesalamine and amoxicillin, ciprofloxacin extended release (XR), metronidazole, or sulfamethoxazole in four open-label, randomized, placebo-controlled, two-period crossover studies." | 2.79 | Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. ( Barrett, K; Corcoran, M; Inglis, S; Martin, P; Pierce, D; Preston, P; Thompson, TN; Willsie, SK, 2014) |
| "The role of antibiotics in the treatment of ulcerative colitis is controversial." | 2.70 | A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. ( Amberiadis, P; Archavlis, E; Christidou, A; Kourtessas, D; Mantzaris, GJ; Petraki, K; Triantafyllou, G, 2001) |
| "Addition of a 6-month ciprofloxacin treatment for ulcerative colitis improved the results of conventional therapy with mesalamine and prednisone." | 2.69 | Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. ( Färkkilä, MA; Hakala, K; Miettinen, TA; Ogren, M; Seppälä, K; Sivonen, A; Turunen, UM; Valtonen, VV; Vuoristo, M, 1998) |
| "Four studies assessed treatment of acute pouchitis." | 2.61 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Holubar, SD; Nguyen, N; Pardi, DS; Singh, S; Zhang, B, 2019) |
| "Patients with pouchitis have a wide range of symptoms, endoscopic and histologic features, disease course, and prognosis." | 2.61 | Prevention and Medical Treatment of Pouchitis In Ulcerative Colitis. ( Benlice, C; Shen, B; Steele, SR, 2019) |
| "Pouchitis is the most frequent long-term complication of IPAA in patients with UC, with a cumulative prevalence of up to 50%." | 2.46 | Diagnosis and management of pouchitis and ileoanal pouch dysfunction. ( Navaneethan, U; Shen, B, 2010) |
| "Pouchitis is a common and long-term complication of ileal pouch-anal anastomosis in patients with underlying ulcerative colitis." | 2.43 | [Diagnosis and medical treatment of pouchitis in ileal pouch-anal anastomosis in patients with ulcerative colitis]. ( Fujii, T; Kawamata, S; Matsushita, M; Okazaki, K; Shimatani, M, 2005) |
| "In general, patients with Crohn's disease are not usually offered IPAA, because recurrence of disease, fistulas, abscesses, and strictures may lead to a higher incidence of pouch failure." | 2.41 | Complications after ileal pouch-anal anastomosis. ( Lichtenstein, GR; Stein, RB, 2000) |
| "The elective treatment for acute pouchitis is antibiotics." | 1.56 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. ( Barreiro-de Acosta, M; Beltrán, B; Chaparro, M; Espín, E; Ferrer Bradley, I; Gisbert, JP; Guarner, F; Gutiérrez, A; Marín-Jimenez, I; Nos, P; Rodríguez-Lago, I, 2020) |
| "Four studies assessed treatment of acute pouchitis." | 1.51 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. ( Holubar, SD; Nguyen, N; Pardi, DS; Singh, S; Zhang, B, 2019) |
| "Pouchitis was classified as acute or chronic pouchitis." | 1.39 | Clinical features and management of pouchitis in Japanese ulcerative colitis patients. ( Bando, T; Ikeuchi, H; Matsuoka, H; Takesue, Y; Tomita, N; Uchino, M, 2013) |
| "Pouchitis is the most common long-term complication after restorative total proctocolectomy and IPAA for ulcerative colitis." | 1.38 | The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis. ( Funayama, Y; Haneda, S; Ogawa, H; Sasaki, I; Shibata, C; Suzuki, H; Takahashi, K; Watanabe, K, 2012) |
| "The incidence of PPI in patients with ulcerative colitis/indeterminate colitis is 5." | 1.35 | Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. ( Bell, AJ; Ciclitira, PJ; Clark, SK; McLaughlin, SD; Nicholls, RJ; Tekkis, PP, 2009) |
| "Pouchitis is the major long-term complication after ileal pouch-anal anastomosis (IPAA) in patients operated on for ulcerative colitis." | 1.32 | CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. ( Baggiolini, M; Campieri, M; Gionchetti, P; Helwig, U; Kühbacher, T; Lammers, K; Rizzello, F; Schreiber, S; Uguccioni, M, 2004) |
| "The medical treatment of acute pouchitis was usually oral metronidazole (250 mg twice daily) for 2 weeks or oral ciprofloxacin (200 mg thrice daily) in patients who could not tolerate metronidazole." | 1.32 | Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients. ( Ikeuchi, H; Nakamura, M; Nakano, H; Noda, M; Uchino, M; Yamamura, T; Yanagi, H, 2004) |
| "Records of 217 patients with mucosal ulcerative colitis who underwent restorative proctocolectomy with a stapled ileal pouch-anal anastomosis without anal mucosectomy from 1987 through 1990 were retrospectively reviewed." | 1.29 | Anal canal inflammation after ileal pouch-anal anastomosis. The need for treatment. ( Fazio, VW; Lavery, IC; Sirimarco, MT; Ziv, Y, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (17.31) | 18.2507 |
| 2000's | 17 (32.69) | 29.6817 |
| 2010's | 18 (34.62) | 24.3611 |
| 2020's | 8 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bar, N | 1 |
| Avraham, Y | 1 |
| Dubinsky, V | 1 |
| Cohen, NA | 1 |
| Weiss, GA | 1 |
| Banon, L | 1 |
| Tulchinsky, H | 1 |
| Maharshak, N | 1 |
| Gophna, U | 1 |
| Dotan, I | 1 |
| Travis, S | 1 |
| Silverberg, MS | 1 |
| Danese, S | 2 |
| Gionchetti, P | 3 |
| Löwenberg, M | 1 |
| Jairath, V | 1 |
| Feagan, BG | 1 |
| Bressler, B | 1 |
| Ferrante, M | 1 |
| Hart, A | 1 |
| Lindner, D | 1 |
| Escher, A | 1 |
| Jones, S | 1 |
| Shen, B | 5 |
| Barnes, EL | 1 |
| Desai, A | 1 |
| Kochhar, GS | 1 |
| Emile, SH | 1 |
| Horesh, N | 1 |
| Freund, MR | 1 |
| Garoufalia, Z | 1 |
| Gefen, R | 1 |
| Khan, SM | 1 |
| Silva-Alvarenga, E | 1 |
| Wexner, SD | 1 |
| Nguyen, N | 2 |
| Zhang, B | 2 |
| Holubar, SD | 4 |
| Pardi, DS | 5 |
| Singh, S | 3 |
| Bohossian, HB | 1 |
| Lopes, EW | 1 |
| Roller, LA | 1 |
| Ananthakrishnan, AN | 1 |
| Zukerberg, LR | 1 |
| Fukushima, K | 1 |
| Saito, T | 1 |
| Kohyama, A | 1 |
| Watanabe, K | 2 |
| Barreiro-de Acosta, M | 1 |
| Marín-Jimenez, I | 1 |
| Rodríguez-Lago, I | 1 |
| Guarner, F | 1 |
| Espín, E | 1 |
| Ferrer Bradley, I | 1 |
| Gutiérrez, A | 1 |
| Beltrán, B | 1 |
| Chaparro, M | 1 |
| Gisbert, JP | 1 |
| Nos, P | 1 |
| Kayal, M | 1 |
| Bhagya Rao, B | 1 |
| Bhattacharya, A | 1 |
| Ungaro, R | 1 |
| Argollo, M | 1 |
| Kotze, PG | 1 |
| Lamonaca, L | 1 |
| Gilardi, D | 1 |
| Furfaro, F | 1 |
| Yamamoto, T | 1 |
| Benlice, C | 1 |
| Steele, SR | 1 |
| Samaha, M | 1 |
| Moloney, M | 1 |
| Guslandi, M | 1 |
| Pierce, D | 1 |
| Corcoran, M | 1 |
| Martin, P | 1 |
| Barrett, K | 1 |
| Inglis, S | 1 |
| Preston, P | 1 |
| Thompson, TN | 1 |
| Willsie, SK | 1 |
| Petersen, AM | 1 |
| Mirsepasi, H | 1 |
| Halkjær, SI | 1 |
| Mortensen, EM | 1 |
| Nordgaard-Lassen, I | 1 |
| Krogfelt, KA | 1 |
| Allam, NG | 1 |
| Eldrieny, EA | 1 |
| Mohamed, AZ | 1 |
| Stroud, AM | 1 |
| Sandborn, WJ | 3 |
| James, J | 1 |
| Kaul, DR | 1 |
| Goldberger, ZD | 1 |
| Saint, S | 1 |
| Skerrett, SJ | 1 |
| Boesler, B | 1 |
| Ott, M | 1 |
| Menges, M | 1 |
| McLaughlin, SD | 1 |
| Clark, SK | 1 |
| Bell, AJ | 1 |
| Tekkis, PP | 1 |
| Ciclitira, PJ | 1 |
| Nicholls, RJ | 1 |
| He, X | 1 |
| Bennett, AE | 1 |
| Lian, L | 1 |
| Cima, RR | 1 |
| Navaneethan, U | 1 |
| Suzuki, H | 1 |
| Ogawa, H | 1 |
| Shibata, C | 1 |
| Haneda, S | 1 |
| Takahashi, K | 1 |
| Funayama, Y | 1 |
| Sasaki, I | 1 |
| So, K | 1 |
| Shepherd, NA | 1 |
| Mandalia, T | 1 |
| Ahmad, T | 1 |
| Uchino, M | 2 |
| Ikeuchi, H | 2 |
| Matsuoka, H | 1 |
| Bando, T | 1 |
| Takesue, Y | 1 |
| Tomita, N | 1 |
| Arora, A | 1 |
| Saluja, SS | 1 |
| Bhardwaj, V | 1 |
| Singh, M | 1 |
| Singh, A | 1 |
| Puri, AS | 1 |
| Helwig, U | 1 |
| Rizzello, F | 2 |
| Lammers, K | 1 |
| Kühbacher, T | 1 |
| Schreiber, S | 1 |
| Baggiolini, M | 1 |
| Uguccioni, M | 1 |
| Campieri, M | 2 |
| Nakano, H | 1 |
| Nakamura, M | 1 |
| Yanagi, H | 1 |
| Noda, M | 1 |
| Yamamura, T | 1 |
| Dignass, AU | 1 |
| Herrlinger, K | 1 |
| Schölmerich, J | 1 |
| Gosselink, MP | 1 |
| Schouten, WR | 1 |
| van Lieshout, LM | 1 |
| Hop, WC | 1 |
| Laman, JD | 1 |
| Ruseler-van Embden, JG | 1 |
| Ohge, H | 1 |
| Furne, JK | 1 |
| Springfield, J | 1 |
| Rothenberger, DA | 1 |
| Madoff, RD | 1 |
| Levitt, MD | 1 |
| Morselli, C | 1 |
| Romagnoli, R | 1 |
| Okazaki, K | 1 |
| Matsushita, M | 1 |
| Kawamata, S | 1 |
| Shimatani, M | 1 |
| Fujii, T | 1 |
| Kolios, G | 1 |
| Manousou, P | 1 |
| Bourikas, L | 1 |
| Notas, G | 1 |
| Tsagarakis, N | 1 |
| Mouzas, I | 1 |
| Kouroumalis, E | 1 |
| Pozdnyakova, O | 1 |
| Garg, A | 1 |
| Mahalingam, M | 1 |
| Lavery, IC | 1 |
| Sirimarco, MT | 1 |
| Ziv, Y | 1 |
| Fazio, VW | 2 |
| Grando, V | 1 |
| Bellaïche, G | 1 |
| Le Pennec, MP | 1 |
| Slama, JL | 1 |
| Ley, G | 1 |
| Nouts, A | 1 |
| Paugam, B | 1 |
| Hurst, RD | 1 |
| Molinari, M | 1 |
| Chung, TP | 1 |
| Rubin, M | 1 |
| Michelassi, F | 1 |
| Mantzaris, GJ | 3 |
| Archavlis, E | 2 |
| Christoforidis, P | 1 |
| Kourtessas, D | 2 |
| Amberiadis, P | 2 |
| Florakis, N | 1 |
| Petraki, K | 2 |
| Spiliadi, C | 1 |
| Triantafyllou, G | 2 |
| Turunen, UM | 1 |
| Färkkilä, MA | 1 |
| Hakala, K | 1 |
| Seppälä, K | 1 |
| Sivonen, A | 1 |
| Ogren, M | 1 |
| Vuoristo, M | 1 |
| Valtonen, VV | 1 |
| Miettinen, TA | 1 |
| Present, DH | 1 |
| Turunen, U | 1 |
| Valtonen, V | 1 |
| Stein, RB | 1 |
| Lichtenstein, GR | 1 |
| Surawicz, CM | 1 |
| Parlak, E | 1 |
| Dağli, U | 1 |
| Ulker, A | 1 |
| Alkim, C | 1 |
| Sahin, B | 1 |
| Christidou, A | 1 |
| Achkar, JP | 1 |
| Lashner, BA | 1 |
| Ormsby, AH | 1 |
| Remzi, FH | 1 |
| Brzezinski, A | 1 |
| Bevins, CL | 1 |
| Bambrick, ML | 1 |
| Seidner, DL | 1 |
| Marteau, P | 1 |
| Seksik, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Amoxicillin Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01442688] | Phase 1 | 62 participants (Actual) | Interventional | 2011-10-07 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01469637] | Phase 1 | 44 participants (Actual) | Interventional | 2011-11-07 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Ciprofloxacin XR Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01402947] | Phase 1 | 30 participants (Actual) | Interventional | 2011-07-25 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Metronidazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01418365] | Phase 1 | 30 participants (Actual) | Interventional | 2011-08-22 | Completed | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis[NCT00583076] | Phase 2 | 19 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Fecal Microbiota Transplantation for the Treatment of Chronic Pouchitis[NCT03538366] | 10 participants (Actual) | Interventional | 2018-05-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | h*ug/ml (Mean) |
|---|---|
| Amoxicillin + MMX Placebo | 27.8 |
| Amoxicillin + MMX Mesalazine/Mesalamine | 28.3 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ug/ml (Mean) |
|---|---|
| Amoxicillin + MMX Placebo | 10.3 |
| Amoxicillin + MMX Mesalazine/Mesalamine | 10.2 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure of how much and how long a drug stays in a body. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | h*ug/ml (Mean) |
|---|---|
| Sulfamethoxazole + MMX Placebo | 786 |
| Sulfamethoxazole + MMX Mesalazine/Mesalamine | 909 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ug/ml (Mean) |
|---|---|
| Sulfamethoxazole + MMX Placebo | 89.1 |
| Sulfamethoxazole + MMX Mesalazine/Mesalamine | 100 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng*h/ml (Mean) |
|---|---|
| MMX Placebo + Ciprofloxacin | 7805 |
| MMX Mesalazine/Mesalamine + Ciprofloxacin | 7934 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng/ml (Mean) |
|---|---|
| MMX Placebo + Ciprofloxacin | 1455 |
| MMX Mesalazine/Mesalamine + Ciprofloxacin | 1433 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng*h/ml (Mean) |
|---|---|
| Metronidazole + MMX Placebo | 217686 |
| Metronidazole + MMX Mesalazine/Mesalamine | 215809 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng/ml (Mean) |
|---|---|
| Metronidazole + MMX Placebo | 28193 |
| Metronidazole + MMX Mesalazine/Mesalamine | 28057 |
11 reviews available for ciprofloxacin and Colitis Gravis
| Article | Year |
|---|---|
A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis.
Topics: Anastomosis, Surgical; Ciprofloxacin; Colitis, Ulcerative; Humans; Metronidazole; Pouchitis; Proctoc | 2023 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Enema; | 2019 |
Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile.
Topics: Ciprofloxacin; Colitis, Ulcerative; Humans; Metronidazole; Patient-Centered Care; Pouchitis; Practic | 2019 |
Prevention and Medical Treatment of Pouchitis In Ulcerative Colitis.
Topics: Anti-Bacterial Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Humans; Male; Metronidazole; | 2019 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Adult; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Enema; Gastrointestinal Agents; Humans; Metro | 2015 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Adult; Ciprofloxacin; Colitis, Ulcerative; Enema; Gastrointestinal Agents; Humans; Metronidazole; Po | 2010 |
Diagnosis and management of pouchitis and ileoanal pouch dysfunction.
Topics: Adenomatous Polyposis Coli; Algorithms; Anti-Infective Agents; Antitrichomonal Agents; Ciprofloxacin | 2010 |
Management of inflammatory bowel disease: does rifaximin offer any promise?
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Clinical Trials as Topic; Colitis, Ulcerative; Crohn | 2005 |
[Diagnosis and medical treatment of pouchitis in ileal pouch-anal anastomosis in patients with ulcerative colitis].
Topics: Acute Disease; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Immunologic Factor | 2005 |
Complications after ileal pouch-anal anastomosis.
Topics: Anastomosis, Surgical; Ciprofloxacin; Colitis, Ulcerative; Crohn Disease; Humans; Male; Metronidazol | 2000 |
Ulcerative colitis and cytomegaloviral esophagitis: two diseases, two randomized, controlled trials.
Topics: Antiviral Agents; Ciprofloxacin; Colitis, Ulcerative; Cytomegalovirus Infections; Drug Therapy, Comb | 1999 |
11 trials available for ciprofloxacin and Colitis Gravis
| Article | Year |
|---|---|
Vedolizumab for the Treatment of Chronic Pouchitis.
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Chroni | 2023 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Double-Blind Method; Escherichia c | 2014 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Clostridium Infections; Clostridium perfringens; Coliti | 2004 |
A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Infective A | 1997 |
Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Colonoscopy; Double-Blind Method; | 1998 |
Of ciprofloxacin and ulcerative colitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Double-Blind Method; Humans | 1999 |
Long-term treatment of ulcerative colitis with ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Double-Blind Method; Humans; Prospective | 1999 |
Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis.
Topics: Adult; Ciprofloxacin; Colitis, Ulcerative; Drug Therapy, Combination; Female; Glucocorticoids; Human | 2001 |
A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Colitis, Ulcer | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female; Humans; Mal | 2001 |
30 other studies available for ciprofloxacin and Colitis Gravis
| Article | Year |
|---|---|
Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Metronidazole; Pouchitis; Proctoc | 2022 |
The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Male; Metronidazole; Pouchitis; P | 2023 |
Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools.
Topics: Abdominal Pain; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Clostridium Infections; Col | 2020 |
Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; DNA Gyrase; DNA | 2020 |
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
Topics: Acute Disease; Advisory Committees; Algorithms; Anti-Bacterial Agents; Biological Products; Budesoni | 2020 |
Clinical Challenge: From Ulcerative Colitis to Crohn's Disease-Like Pouch Inflammation.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Colitis, Ulcerative; Crohn Di | 2021 |
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Enema; | 2019 |
Long-term antibiotic therapy in late onset pouch-urethral fistula after ileoanal anastomosis for ulcerative colitis may be effective and well tolerated.
Topics: Adult; Anal Canal; Anastomosis, Surgical; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; | 2013 |
Role of probiotics in the management of pouchitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Intestines; Metronidazol | 2014 |
Effect of combination therapy between thyme oil and ciprofloxacin on ulcer-forming Shigella flexneri.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Ciprofloxacin; Colitis, Ulcerative; Colon; Drug Syne | 2015 |
CLINICAL PROBLEM-SOLVING. Back to Nature.
Topics: Adult; Anorexia; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; | 2015 |
Segmental haemorrhagic colitis under ciprofloxacin therapy.
Topics: Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Colonoscopy; Diagnosis, Different | 2009 |
Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Budesonide; Ciprofloxacin; Colitis, Ul | 2009 |
Recurrent cytomegalovirus infection in ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Cytomegalovirus Infections; Dietary Supplements | 2010 |
The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Colonic Pou | 2012 |
Suppurative granulomatous inflammation in the ileo-anal pouch.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Female; Gr | 2013 |
Clinical features and management of pouchitis in Japanese ulcerative colitis patients.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Age of Onset; Aged; Anti-Bacterial Agents; Asian Peop | 2013 |
Malakoplakia masquerading as ulcerative colitis in an immunocompetent child.
Topics: Adolescent; Ciprofloxacin; Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Gas | 2014 |
CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue.
Topics: Adult; Antineoplastic Agents; Chemokine CCL2; Chemokine CXCL10; Chemokines, CC; Chemokines, CXC; Cip | 2004 |
Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female | 2004 |
[Ulcerative colitis. Chronic active course].
Topics: Administration, Oral; Adult; Age Factors; Anti-Infective Agents; Azathioprine; Child; Chronic Diseas | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Clinical management of pouchitis.
Topics: Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Diagnosis, Differential; H | 2004 |
Association between fecal hydrogen sulfide production and pouchitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Feces; Female; Humans; Hydrogen Sulfide; | 2005 |
Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium.
Topics: Adult; Animals; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Colon; Epithelial Cells; | 2006 |
Nodular vasculitis - a novel cutaneous manifestation of autoimmune colitis.
Topics: Anti-Bacterial Agents; Autoimmune Diseases; Biopsy; Ciprofloxacin; Colitis, Ulcerative; Female; Huma | 2008 |
Anal canal inflammation after ileal pouch-anal anastomosis. The need for treatment.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Anal Canal; Biopsy; Ciprofloxacin; Colitis, Ulcerat | 1995 |
[Ulcerative hemorrhagic proctitis caused by Klebsiella oxytoca after treatment with an amoxicillin-clavulanic acid combination].
Topics: Adult; Amoxicillin; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Colitis, Ulcerative; Drug Resi | 1994 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Ciprofloxacin as a treatment for ulcerative colitis-not yet.
Topics: Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Randomized Controlled Trials as T | 1998 |
[Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin | 2001 |